OTCMKTS:SKBI - Skystar Bio-Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week Range$0.0001 - $0.05
Volume10,020 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-17.87
Skystar Bio-Pharmaceutical Company researches, develops, produces, markets, and sells veterinary healthcare and medical care products in the People's Republic of China. The company offers micro-organism products, veterinary medicines for poultry and livestock, feed additives, and bio-pharmaceutical veterinary vaccines. It markets its products through distributers and franchise distributors, as well as directly to customers. The company is headquartered in Xi'an, the People's Republic of China.

Receive SKBI News and Ratings via Email

Sign-up to receive the latest news and ratings for SKBI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:SKBI
Previous SymbolNASDAQ:SKBI
CUSIPN/A
Phone86-29-8819-3188

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares8,700,000
Market Cap$0.00
OptionableNot Optionable

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Frequently Asked Questions

What is Skystar Bio-Pharmaceutical's stock symbol?

Skystar Bio-Pharmaceutical trades on the OTCMKTS under the ticker symbol "SKBI."

Has Skystar Bio-Pharmaceutical been receiving favorable news coverage?

News coverage about SKBI stock has been trending somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Skystar Bio-Pharmaceutical earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news articles about the healthcare company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.

Who are some of Skystar Bio-Pharmaceutical's key competitors?

Who are Skystar Bio-Pharmaceutical's key executives?

Skystar Bio-Pharmaceutical's management team includes the folowing people:
  • Mr. Weibing Lu, Chairman and Chief Exec. Officer (Age 55)

How do I buy shares of Skystar Bio-Pharmaceutical?

Shares of SKBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Skystar Bio-Pharmaceutical's official website?

The official website for Skystar Bio-Pharmaceutical is http://www.skystarbio-pharmaceutical.com.

How can I contact Skystar Bio-Pharmaceutical?

Skystar Bio-Pharmaceutical's mailing address is RM 10601 JIEZUO PLAZA NO. 4 FENGHUI ROAD SOUTH, XIAN F4, . The healthcare company can be reached via phone at 86-29-8819-3188 or via email at [email protected]


MarketBeat Community Rating for Skystar Bio-Pharmaceutical (OTCMKTS SKBI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Skystar Bio-Pharmaceutical and other stocks. Vote "Outperform" if you believe SKBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SKBI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel